Faculty

Yael N. Kusne, M.D., Ph.D.

Clinical Studies

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry To Describe Patient Experience And Clinical Outcomes Among Patients With CML Receiving Approved First Or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy Rochester, MN This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Clonal Hematopoiesis (CH) And Hematological Toxicity After Genotoxic Cancer Therapy Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN
The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry To Describe Patient Experience And Clinical Outcomes Among Patients With CML Receiving Approved First Or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy Scottsdale/Phoenix, AZ Jacksonville, FL This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.